CytoSorbents Expands Direct Sales of CytoSorb to Belgium and Luxembourg

CytoSorbents Corporation, a Monmouth Junction-based critical care immunotherapy leader commercializing its flagship CytoSorb® extracorporeal cytokine adsorber to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the addition of Belgium and Luxembourg to its direct sales territories.  CytoSorb is now distributed in 42 countries worldwide.

Dr. Christian Steiner, Vice President of Sales and Marketing of CytoSorbents stated, “Expansion of direct sales into Belgium and Luxembourg, two countries that are on the western border of Germany, is the natural result of our strong CytoSorb sales in neighboring Germany, Austria, and Switzerland with our own dedicated sales force.  We have been working with key opinion leaders in major hospitals in these countries for some time, and expect these territories to be a great opportunity for the company while immediately contributing to higher margin sales growth.”

Together, Belgium and Luxembourg have a combined population of approximately 12 million people.  Both countries provide healthcare insurance to their citizens primarily through public insurance funded through social security, with the option of additional coverage through private insurance.  With 113 acute care hospitals in Belgium, it represents a focused market for CytoSorbents to target with its own direct sales force.

Related Articles: